Antibody Drug Conjugate Market Analysis, Size, Share, and Forecast 2031

Comments · 8 Views

The Antibody Drug Conjugate Market in 2023 is US$ 10.50 billion, and is expected to reach US$ around 35 billion by 2031 at a CAGR of 19.6%.

The Antibody Drug Conjugate Market in 2023 is US$ 10.50 billion, and is expected to reach US$ around 35 billion by 2031 at a CAGR of 19.6%.

FutureWise Research published a report that analyzes Antibody Drug Conjugate Market trends to predict the market's growth. The report begins with a description of the business environment and explains the commercial summary of the chain structure. Based on the market trends and driving factors presented in the report, clients will be able to plan the roadmap for their products and services taking into account various socio-economic factors.

Additionally, it illustrates the corporate profiles and situation of competitive landscape amongst numerous associated corporations including the analysis of market evaluation and options associated with the worth chain. This Antibody Drug Conjugate research report provides insights on market overview, market segmentation, current and future pricing, growth analysis, competitive landscape and other such premium insights within the forecast period.

 

Request a Sample Report @ Request for Antibody Drug Conjugate Market Sample

 

Antibody Drug Conjugate Market Segmentation:

By Type

·        Monoclonal Antibodies

·        Linker

·        Drug/Toxin

·        Others

By Application

·        Leukemia

·        Acute Myeloid Leukemia (AML)

·        Chronic Myeloid Leukemia (CML)

·        Acute Lymphocytic Leukemia (ALL)

·        Chronic Lymphocytic Leukemia (CLL)

·        Prostate Cancer

·        Kidney Cancer

·        Pancreas Cancer

·        Ovary Cancer

·        Glioblastoma

·        Lung Cancer

·        Colon Cancer

·        Breast Cancer

·        Skin Cancer

·        Solid Tumors

·        Multiple Myeloma

·        Lymphoma

By Product

·        Adcetris

·        Kadcyla

·        Others

By Technology

·        ImmunoGen Technology

·        Seattle Genetics Technology

·        Immunomedics Technology

·        Others

By End User

·        Hospitals

·        Specialized Cancer Centers

·        Academic Research Institutes

·        Biopharmaceutical Companies

·        Others

By Region

·        North America

·        Europe

·        Asia-Pacific

·        Latin America

·        Middle East and Africa

 

Major players included in the Antibody Drug Conjugate Market:

·        Seattle Genetics

·        ImmunoGen, Inc.

·        Roche Holding AG

·        Genentech

·        Concortis Biotherapeutics

·        AGENSYS, INC.

·        Antikor

·        Immunomedics

·        Pfizer Inc.

·        Celldex Therapeutics

·        Millennium Pharmaceuticals

·        AbbVie Inc.

·        Bayer HealthCare

·        Astellas Pharma/Agensys

·        Progenics Pharmaceuticals

·        Mersana Therapeutics

·        Synthon

·        Heidelberg Pharma

·        Oxford BioTherapeutics

 

Please visit full report of the Antibody Drug Conjugate market @ Visit Antibody Drug Conjugate Market

Competitive Landscape:

·         Tier one players - market players with a significant share of the market

·        

Comments